Analytical and Chemical Enhancements to Improve Efficacy and Accuracy of Therapeutic Oligonucleotides
See how top pharma players are addressing impure, unstable, and off-target oligos
Boosting the Efficacy of Safe, Scalable, & Precise Vaccines
Innovations in mRNA Technology, RNA Therapeutics, and Cancer Immunotherapy for 2024
.png)
Tumbler: A Highly Customizable Antibody Optimization Suite
On-demand presentation, presented by Michali Izhaky, Bioinformatics Scientist at Charles River
Leading Innovations in Fab, ScFv, & VHH Production and Engineering
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy
On-demand webinar presented by Ritwika Biswas, Field Application Scientist at Sino Biological
Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Oligo Chemistry
Targeted Delivery with FORCE: Novel Approaches in Oligo Therapeutics
How are oligo therapeutics revolutionising genetic disease treatments through precise targeting and transformative therapies? In this article, we explore how they provide precise gene expression interference for untreatable conditions by directly targeting disease-associated proteins and genetic mutations.
Manufacturing & Bioprocessing
Sustainability in Cell Therapy Manufacture: Improving Process Efficiency for Cell Line Development
Improving process efficiency is a key approach to factor in when looking at how cell therapy manufacture can be made more sustainable.
How Will Commercialisation Impact COVID-19 Vaccine Prices in the US?
We take a look at how the commercialisation of COVID-19 vaccines in the US will impact the price of the vital therapeutic.
NextGen Therapeutics
WuXi Biologics and GSK Enter License Agreement for Bispecific Development
The Pharma giants have partnered to advance the development of bispecific T cell engaging antibodies using WuXi’s platforms.
Drug Discovery & Development
Another Partnership from Takeda and F-Star Therapeutics to Look for Antibody-Based Therapies
The collaboration includes an upfront payment, milestone-dependent funds, and commercial royalties for F-star.
Drug Discovery & Development
Immune Cell Types: Their Opportunities for Therapeutic Use in Oncology
An introduction to the various cell types in the immune system and the opportunities to harness them in immuno-oncology therapies.
BrainStorm Hope to Mimic Biogen's Accelerated Approval of ALS Drug
The biotech company BrainStorm is seeking regulatory approval from the FDA for its cell therapy, NurOwn, which has been developed for the treatment of ALS.
NextGen Therapeutics
T Cell Engagement and Activation: New Developments
As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape.
Antibody & Protein Engineering
Accelerating time to market through process innovation
On-Demand Workshop presented by Andreas Castan, Strategic Technologies Director at Cytiva, Cauroline Hausner, Business Development Manager, Aseptic Filling at Cytiva, Ola Tuvesson, Chief Technology Officer at NorthX Biologics & Sofie Östemar, Product Manager, Connected & Continuous at Cytiva
Gene Therapy Development
Replacing the EU's Clinical Trials Directive: A Sea Change in Clinical Trial Execution
The EU's Clinical Trials Regulation has replaced the union's former Clinical Trials Directive, introducing a centralised application process which aims to ensure consistent timelines for clinical trial reviews.
Antibody & Protein Engineering
Xentria and Meitheal Collaborate on Breakthrough Lung Disease Treatment
Xentria and Meitheal partner to develop a breakthrough drug for pulmonary sarcoidosis, aiming to improve patient outcomes.
3D Cell Culture
3D Cell Model Approaches for Disease Monitoring and Detection
Given the widespread incidence of cancers and cardiovascular diseases, having sufficient means to model their behaviour is vital to the development of new treatments. Maintaining tissue contexts in disease modelling is crucial for developing a comprehensive understanding of how different diseases behave.